By SmashMeals Editorial — 2026-09-30 — Health & Nutrition
The short answer
No single symptom can tell you whether semaglutide is or is not working. In a 60-week randomized trial, some early appetite effects became less pronounced over time, yet participants receiving semaglutide still consumed fewer calories and had substantially greater weight loss than placebo at week 60. Medication questions and dose decisions belong with the prescribing clinician.
Key facts
- The randomized placebo-controlled trial followed participants for 60 weeks.
- At week 20, semaglutide was associated with lower hunger and greater fullness than placebo.
- By week 60, several subjective appetite differences were no longer statistically significant.
- Despite that change, energy intake remained lower and weight loss remained substantially greater with semaglutide than placebo.
- The findings do not mean everyone will experience the same appetite pattern or that returning hunger should be ignored.
KINGSPORT, Tenn., Sept. 30, 2026 — “Why am I hungry again?” is an understandable question during long-term GLP-1 treatment. A 60-week randomized controlled trial of semaglutide 2.4 mg offers useful context: the powerful appetite differences seen earlier in treatment did not remain equally strong on every subjective measure at week 60.
That did not mean the treatment groups suddenly looked the same. Participants receiving semaglutide still consumed fewer calories and had substantially greater weight loss than those receiving placebo.
This is educational reporting on a clinical trial, not medication advice. Never change a prescription or dose based on this article.
What changed between week 20 and week 60
Earlier in the trial, semaglutide participants reported lower hunger, greater fullness and better control of eating. By week 60, several of those subjective appetite differences were no longer statistically significant. Long-term physiology and behavior are more complicated than the idea that a medication should make someone feel exactly the same every day indefinitely.
Energy intake still differed
The key nuance is that subjective hunger is not the same thing as total energy intake. Even as some appetite ratings converged, the semaglutide group continued to consume fewer calories than placebo during the study's standardized food-intake testing.
What this means for food planning
A static meal plan may become less useful when appetite, tolerance, activity and treatment stage change. The practical approach is to keep nutrition information visible and adjust portions and meal choices within the plan set with your care team.
For more context, read our semaglutide food guide, the latest GLP-1 nutrition guidance, and our GLP-1 food hub.
Commentary, not medical advice
The SmashMeals perspective
For a food company, the useful lesson is not to interpret medication effectiveness. It is to recognize that appetite can change over a long treatment journey. A flexible weekly menu with visible nutrition information lets customers adjust food choices without pretending one static 'GLP-1 meal plan' fits every week forever.
Frequently asked questions
Does feeling hungry again mean semaglutide stopped working?
Not necessarily. Appetite is only one part of treatment response. The 60-week trial found some subjective appetite differences narrowed over time while energy intake and weight outcomes still differed from placebo. Discuss meaningful changes with your prescriber.
Should I change my semaglutide dose if hunger returns?
Dose changes are medical decisions. Do not change a prescription based on an article or hunger alone; contact the prescribing clinician.
Sources & experts referenced
Sources are included for verification. No expert listed here endorses SmashMeals.
- Long-term effects of semaglutide 2.4 mg on energy intake, appetite, and control of eating in adults with obesity — The American Journal of Clinical Nutrition
Why it matters: Primary randomized controlled trial examining energy intake and appetite over 60 weeks.